1-acetyl-6-[(3-bromophenyl)ethynyl]-1,2,3,4-tetrahydroquinoline | 937594-22-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1-acetyl-6-[(3-bromophenyl)ethynyl]-1,2,3,4-tetrahydroquinoline
• 英文别名: 1-[6-[2-(3-bromophenyl)ethynyl]-3,4-dihydro-2H-quinolin-1-yl]ethanone
• CAS: 937594-22-4
• 化学式: C₁₉H₁₆BrNO
• 分子量: 354.246
• InChiKey: YIHLODVXHSHMOU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Novel 2-Amino-Imidazole-4-One Compounds and Their Use in the Manufacture of a Medicament to Be Used in the Treatment of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration and Dementia
  申请人：Berg Stefan

  公开号：US20090233930A9

  公开（公告）日：2009-09-17

  This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.

  本发明涉及具有以下结构式I的新化合物，以及它们的药学上可接受的盐、组合物和使用方法。这些新化合物提供了治疗或预防认知障碍、阿尔茨海默病、神经退行性和痴呆症的方法。
• NOVEL 2-AMINO-IMIDAZOLE-4-ONE COMPOUNDS AND THEIR USE IN THE MANUFACTURE OF A MEDICAMENT TO BE USED IN THE TREATMENT OF COGNITIVE IMPAIRMENT, ALZHEIMER'S DISEASE, NEURODEGENERATION AND DEMENTIA
  申请人：Astra Zeneca AB

  公开号：EP1979324A2

  公开（公告）日：2008-10-15
• [EN] NEW COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES
  申请人：ASTRAZENECA AB

  公开号：WO2007058602A2

  公开（公告）日：2007-05-24

  [EN] This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
  [FR] La présente invention concerne de nouveaux composés ayant la formule structurale I ci-dessous : et leurs sels pharmaceutiquement acceptables, des compositions et des procédés d'utilisation. Ces nouveaux composés permettent un traitement ou une prophylaxie de troubles cognitifs, de la maladie d'Alzheimer, de la neurodégénérescence et de la démence.